Transgenic mouse models for diseases caused by mtDNA mutations and related methods
View Patent ↗Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.
1. A a mouse whose mitochondrial DNA (mtDNA) comprises engineered mutations, wherein said mutations comprise:
(a) a homoplasmic COI T6589C missense mutation and,
(b) a T deletion reversion of a 1388insC mutation (1388incCdelT) in the ND6 gene, wherein said mouse has mtDNA from mouse strains NZB and 129 mixed in the same cytoplasm; and
wherein said mouse exhibits hypertrophic cardiomyopathy and mitochondrial abnormalities.
2. A mouse according to claim 1 wherein said mouse is 50-50 heteroplasmic for an ND6 13885insC frameshift mutation and an ND6 13885insCdelT reversion mutation.
3. A mouse according to claim 1 wherein said mouse is a female mouse that has been backcrossed to C57BL/6J males.
4. A method for determining potential effectiveness of a candidate therapeutic in treating, delaying the onset of or lessening the severity of hypertrophic cardiomyopathy, said method comprising the steps of:
A) providing a mouse according to claim 1 ;
B) administering the candidate therapeutic to the mouse; and
C) determining whether the candidate therapeutic was effective in treating, delaying the onset of or lessening the severity of hypertrophic cardiomyopathy, or of a symptom of hypertrophic cardiomyopathy, by comparing said mouse to one or more other mice according to claim 1 that was or were not administered the candidate therapeutic.
5. A method according to claim 4 wherein the candidate therapeutic comprises a drug.
6. A method according to claim 4 wherein the candidate therapeutic comprises a chemical composition.
7. A method according to claim 4 wherein the candidate therapeutic comprises a biologic.
8. A method according to claim 4 wherein the candidate therapeutic comprises a vaccine.
9. A method according to claim 4 wherein the candidate therapeutic comprises a therapeutic device.